Biographical Sketch
Robert Dreicer, MD, FACP, is Chairman of the Department of Solid Tumor Oncology at Cleveland Clinic and a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine. Dr. Dreicer is board-certified in internal medicine and medical oncology. His areas of specialization are the management of genitourinary malignancies and the design and conduct of clinical trials in urologic oncology. Dr. Dreicer received his B.S. degree at Colorado State University and his MS degree at the University of Texas Graduate School of Biomedical Sciences in Houston, Texas. He received his medical degree from the University of Texas Medical School at Houston.
He completed an internal medicine residency at Indiana University in Indianapolis, followed by a medical oncology fellowship at the University of Wisconsin Clinical Cancer Center in Madison, Wisconsin. He joined the Division of Hematology/Oncology at the University of Iowa in 1989 and upon his departure He was a tenured Associate Professor of Medicine and Associate Division Director of Hematology/Oncology. Dr. Dreicer was appointed as a Staff Physician in Hematology/Oncology with a secondary appointment in the Urologic Institute.
He was appointed Director of the Genitourinary Medical Oncology program and Associate Director of the Experimental Therapeutics Program in 2000 and Chairman of the Department of Solid Tumor Oncology in January of 2006 . Dr. Dreicer has published widely in genitourinary oncology, and is the principle investigator of a large number of ongoing studies in genitourinary neoplasms. He is the Chair of the Bladder Subcommittee of the Eastern Cooperative Oncology Group and a Fellow of the American College of Physicians.
He was Chair of the Steering Committee for ASCO's 2008 GU Oncology Meeting. He is, an Associate Editor of Urology, and a member of the editorial boards of the Journal of Clinical Oncology, the New England Journal of Medicine's Journal Watch Hematology/Oncology and The Journal Of Supportive Oncology. He is a member of the scientific advisory board of Transgene.
Specialty Interests
experimental therapeutics, urologic oncology, Experimental Therapeutics
Industry Relationships
Cleveland Clinic physicians and scientists may collaborate
with the pharmaceutical or medical device industries
to help develop medical breakthroughs or provide
medical education about recent trends. The
collaborations are reviewed as part of the Cleveland
Clinic’s procedures. The Cleveland Clinic publicly
discloses payments to its physicians and scientists
for speaking and consulting of
$5,000 or more per year, and any equity, royalties,
and fiduciary relationships in companies with which
they collaborate. In publicly disclosing this
information, the Cleveland Clinic tries to provide
information as accurately as possible about its
doctors’ connections with industry and those of their
immediate family members. As of 7/31/2008, Dr.
Dreicer has reported the financial relationships
with the companies listed below. Patients should feel
free to contact their doctor about any of the
relationships and how the relationships are overseen
by the Cleveland Clinic. To learn more about the
Cleveland Clinic’s policies on collaborations with
industry and innovation management, go to
our Integrity in Innovation page.
Consulting. Dr. Dreicer receives fees of $5,000 or more per year as a paid consultant or speaker for the following companies:
Sanofi-Aventis US Inc.
